UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced its intention to acquire Spark in February, but has had to keep pushing back the completion date as the FTC in the US and the CMA in the ... In a statement from the CMA, the antitrust authority said: “While gene therapy treatments

Pfizer, Flynn face reinstatement of £90m CMA fine

The case dates back to 2015, when the Competition and Markets Authority (CMA)   accused the two companies of dramatically raising the price of phenytoin sodium, a drug that has been used ... A  report in the Financial Times says the CMA is arguing

Roche moving closer to approval of Spark takeover; report

Competition and Markets Authority (CMA) have taken their time to probe antitrust issued raised by the deal. ... The CMA has set a deadline of mid-December for a decision on the first phase of its review of the acquisition, which could be the end of the

UK government raises concerns about Illumina’s $1.2bn takeover of PacBio

added. Following the CMA's provisional findings, it has invited comments on possible remedies by 7 November 2019. ... Illumina had originally planned to close the transaction in mid-2019, but this was stalled by the CMA's investigation, which began in

Aspen to pay millions to NHS following drug pricing investigation

According to the CMA, thousands of patients rely on the medicine, which is used to treat primary or secondary adrenal insufficiency (Addison’s Disease). ... Following the investigation, the CMA has accepted Aspen’s offer of commitments to resolve a

Strengthening business competition and reducing anti-competitive practices

A firm pharma focus. The CMA’s focus on the pharmaceutical industry is not surprising. ... cartel activities and serious abuses of a dominant position, which the CMA categorises.

Five things you didn't realise you already know about influencer marketing

The Advertising Standards Authority (ASA) and Competitions and Markets Authority (CMA) have been applying stricter guidelines and monitoring the industry more closely. ... Always seek advice from the agency you’re working with or directly from the ASA

Stakeholder dialogue in Europe’s adaptive pathways pilot

The use of real-world evidence (RWE) as a complement to clinical trial data to support reimbursement decisions after Conditional Marketing Authorisation (CMA) is granted.

Drug R&D

Healthcare systems